Clinical progress note: Respiratory syncytial virus.

Abstract

Globally, respiratory syncytial virus (RSV) is responsible for more than 3.6 million hospitalizations and 100,000 deaths every year. Since 2023, three immunizations have been approved for clinical use, each targeting a different patient population. These newly available RSV immunizations are poised to prevent hospitalizations, reduce costs for healthcare systems, and save lives. This review will discuss the evidence behind these immunization strategies and examine their potential to blunt the global impact from RSV.